Free Trial!
Today’s Best Stocks To Trade! Click Here
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.
CYBERHAND TECHNOLOGIES INTERNATIONAL (OTC: CYHA | Quote | Chart | News | PowerRating) "Up 44.74% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/CYHA.php
CyberHand Technologies International, Inc., through its Canadian operating subsidiary, design, market, sell, distribute and provide service for new consumer electronic technologies. These products use innovative ergonomic designs and technologies that are superior to other products in the market. The initial product offering includes: Computer Game Controllers that are 40% more responsive then the competitor's products; Wireless Keyboards for Personal Digital Assistants (PDAs"); Ergonomic Computer Mouse Product line that eliminates computer related Respective Stress Injuries; and Related Software Upgrades and other peripherals such as Keyboards, Cameras and Scanners. The products are patent protected in both Canada and the United States.
CYHA News:
June 10 - Black Widow Prerelease for Gamers Who Want an Edge
Cyberhand Technologies International Inc. (OTC: CYHA), a design, marketing and distribution company providing new consumer electronic technologies using innovative ergonomic designs, today announced its subsidiary, Cyberhand Robotics, has moved to the field testing of its first controller on the gaming and engineering design marketplace. The first product is called the "Black Widow" and will be accompanied by a Pro version almost immediately for more serious gamers. It is far faster than any gaming controller offered at any price, cannot cause any of the five carpel tunnels of any of the RMS problems normally associated with fast accurate use of pointing devices and allows substantially longer game play without fatigue. This is the first in a line of patented advanced controllers that will be offered by the company.
"Cyberhand will be releasing 500 of its Black Widow controllers to qualified testers who will receive a fifty percent (50%) discount to release retail for their participation and control testing in advance of its fall release. They must sign a strict non-disclosure agreement and provide the company feedback and suggestions. All interested testers will be able to sign up on the company website. The Controller allows you to fight harder, move faster, dodge at lightning speed, play for hours without fatigue or pain and crush your opponents. You will be able to design faster, connect pieces easier and relax while you do complex on-screen tasks like you have never experienced them before. At Cyberhead, we invite you to come and test the Black Widow and help change the world of gaming pointing devices forever!" said Patrick Burke, Inventor at Cyberhand Technologies International Inc.
ABOUT CYBERHAND ROBOTICS
Cyberhand Robotics Corporation, a subsidiary of Cyberhand Technologies International Inc., is a new Company that consists of all the technology and intellectual property related to the development of an Ergonomic Computer Mouse and a line of Computer Game Controllers. A unique feature of the Ergonomic Computer Mouse is its ability to eliminate computer related respective stress injuries such as carpal tunnel syndrome. The Computer Game Controllers integrate hand movement which, in turn, permit a variety of control functions to be performed by a single left or right handed operation resulting in a significant increase in response times over competing products making it the fastest, most intelligent, and most comfortable first person shooter controller on the market. In the gaming world, where split second timing and agility determine the winners and losers, the Company's game controllers place users at the top of any game as they are 40% more responsive than competitor products. The markets for the Company's products are huge, consisting of the Computer Peripheral market with over 600,000,000 users worldwide and the Computer Gaming Peripherals market estimated at $6 billion dollars in the U.S. alone, with this market growing at the rate of 34% per year.
ACCENTIA BIOPHARMACEUTICALS (NASD: ABPI | Quote | Chart | News | PowerRating) "Up 23.85% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNasal, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida.
ABPI News:
June 11 - Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin's lymphoma (NHL), an often fatal blood cancer.
The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.
According to Steven Arikian, M.D., Chairman and CEO of Biovest International, "In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).
"Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm," stated Dr. Arikian.
Dr. Angelos Stergiou, Biovest's Vice President, Product Development, added, "We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm."
ABOUT BIOVAXID
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
ABOUT BIOVEST INTERNATIONAL INC.
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID , which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI | Quote | Chart | News | PowerRating) "Up 19.51% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php
Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkin's lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. The company has a cooperative research and development agreement with the National Cancer Institute for the development and commercialization of patient-specific vaccines for the treatment of non-Hodgkin's low-grade follicular lymphoma. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc.
BVTI News:
June 11 - Biovest Reports Blinded Results for Phase Three Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin's lymphoma (NHL), an often fatal blood cancer.
The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.
According to Steven Arikian, M.D., Chairman and CEO of Biovest International, "In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).
"Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm," stated Dr. Arikian.
Dr. Angelos Stergiou, Biovest's Vice President, Product Development, added, "We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm."
ABOUT BIOVAXID
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
ENZYME ENVIRONMENTAL SOLUTIONS (OTC: EESO | Quote | Chart | News | PowerRating) "Up 50.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/EESO.php
Enzyme Environmental Solutions is a U.S.-based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. EESO strives to become a leader in ecological friendly or "green products" targeting the industrial and agricultural markets. It is the company's goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is its number one marketing strategy.
EESO News:
June 11 - Enzyme Environmental Solutions Finalizes Agreement With Canada's Largest Food Service Brokerage
Enzyme Environmental Solutions Inc. (OTC: EESO | Quote | Chart | News | PowerRating) CEO S. Jared Hochstedler announced that the company has finalized the agreement to supply International Pacific Sales, LTD with sustainable cleaning products.
Hochstedler commented, "I am extremely pleased to announce that EESO has now contracted with International Pacific Sales, LTD, www.internationalpacificsales.com, to supply our enzyme based cleaning products across all of western Canada."
Hochstedler continued, "This is another huge step for the company. I have been negotiating with International Pacific Sales, LTD for several weeks and am proud to be associated with such a prestigious company. International Pacific Sales, LTD is well known for its integrity, stability and high standards of professionalism. Mike Discroll, President of IPS, was the first Food Service broker to receive the 'We Care Hall of Fame Award.'"
The Company projects revenues between $2 and $4 million over the next 12 months with initial revenues beginning in July and in full swing by the end of the third quarter 2008.
"This continues to be an exciting time for our company. I am getting calls from in and outside the U.S. inquiring about our products. There has been much effort from everyone absorbing the efforts of our sales team that took place in the preceding months. The build out of the office and warehouse is just about completed and we have scheduled our Grand Opening for June 27, 2008. However all shareholders should feel free to stop in anytime," stated Hochstedler.
"I will be providing some updated revenue projections for 2008 and 2009 in the coming days; however I am pleased with the progress we have made thus far. On line sales have continued to outpace my expectations and I am pleased to relay we have received very positive feedback concerning the effectiveness of our products," concluded Hochstedler.
CELSIUS HOLDINGS INCORPORATED (OTCBB: CSUH | Quote | Chart | News | PowerRating) "Up 50.42% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/CSUH.php
Celsius Holdings, Inc., through its subsidiaries, Celsius Inc. and Celsius Netshipments, Inc., engages in the production, distribution, and marketing of functional beverages in the United States. The company offers CelsiusR, a calorie burning soda, which is available in cola, ginger ale, lemon/lime, orange, and wild berry flavors. It also sells its products through the Internet. The company was founded in 2004 and is based in Delray Beach, Florida.
CSUH News:
June 10 - 4th Clinical Study on Celsius Shows Additional Benefits with Exercise
Celsius Enhances 10-Week Exercise Program; Delivering More Loss of Fat Mass and More Gain of Muscle Mass
Celsius Holdings, Inc. (OTCBB: CSUH | Quote | Chart | News | PowerRating) reported the preliminary results of yet another completed phase of scientific research, conducted at the Metabolic and Body Composition Laboratory of the Department of Health and Exercise Science, at the University of Oklahoma (Norman, OK). At a meeting of the International Society of Sports Nutrition held in Las Vegas, Nevada, a fourth clinical study of Celsius, the original calorie burning beverage, was unveiled showing that consumption of Celsius as a pre-workout beverage resulted in dramatic improvements in the benefits of exercise among a test group of previously sedentary individuals.
The first phase of the study showed that drinking a single 12oz. serving of Celsius per day for 10 weeks dramatically improves the benefits of light to moderate exercise. The test subjects consuming Celsius lost significantly more fat mass and gained more muscle mass than subjects drinking the placebo, and significantly improved their cardiovascular endurance during exercise.
According to the preliminary findings of the study, those subjects consuming a single serving of Celsius lost significantly more fat mass and gained significantly more fat-free mass (muscle mass) than those subjects consuming the placebo - a 93.8% greater loss in fat and 50% greater gain in fat-free mass, respectively. The study also confirmed that subjects consuming Celsius significantly improved measures of cardio-respiratory fitness (VO2peak) and the ability to delay the onset of fatigue when exercising to exhaustion (time-to-exhaustion). In fact, the Celsius group outperformed those consuming the placebo by 62.5% for VO2peak and 32.5% for time-to-exhaustion.
Celsius Holdings, Inc. has previously reported on breakthrough findings on other clinical studies dating back to June 11, 2005, when its first clinical study was presented at a meeting of the International Society of Sports Nutrition in New Orleans. In addition to showing that a single 12oz. serving of Celsius burns up to 100 calories, additional studies have shown that the impact of Celsius does not attenuate and that test subjects showed the calorie burning benefits of Celsius over a 28-day period, with no clinically adverse changes to important health markers.
This most recent 10-week blinded placebo-controlled study was conducted on a total of 37 previously sedentary men and women. Subjects were randomly assigned into one of two groups: Group 1 consumed one serving of Celsius per day, and Group 2 consumed one serving of an identically flavored and labeled placebo beverage. Both groups participated in 10 weeks of combined aerobic and weight training, following the American College of Sports Medicine guidelines for previously sedentary adults. Fifteen minutes prior to each workout, participants consumed Celsius or the placebo; on non-training days, subjects consumed one beverage at any time of their choosing. Subjects' diet was left uncontrolled (i.e. subjects were not instructed to change their diet).
"This study suggests that Celsius provides a significant, additive adaptation to the benefits of regular exercise," stated Jeffrey R. Stout, Ph.D., who served as the Chief Researcher on the study, at the University of Oklahoma. "Specifically, consuming Celsius prior to exercise appears to augment ones' training response to both aerobic and resistance (weight) training. Furthermore," said Stout, "because we didn't observe a statistically significant difference in strength between groups, but instead found significant improvements in body composition and cardiorespiratory fitness in those consuming the Celsius beverage, there appears to be preferential sequestering of fat for fuel, occurring both during exercise and while at rest. The same findings were previously reported out of Dr. Kerkisk's lab." Dr. Stout concluded by stating, "these are very interesting findings that, in my opinion, will set the tone for how people maximize their workouts. - Now it can be scientifically supported that, by consuming a pre-workout calorie burning beverage, a person can improve their response to exercise; however, these claims are unique to Celsius."
"This latest clinical study, the fourth one with Celsius, exemplifies our commitment to solid clinical research. It clearly extends the proven functionality of Celsius to improving the benefits of regular exercise. This study confirms what the scientists have always told us, but the results are significantly better than what we anticipated," said Steve Haley, CEO of Celsius, Inc. "This most recent study, where we combined Celsius and exercise, was the next logical step in clinical research and further demonstrates our commitment to providing healthier choices so people can easily make lifestyle changes, live healthier lives and attain their fitness goals."
ABOUT CELSIUS
Celsius, the original, great tasting calorie burner, is a healthier choice that has been clinically shown to burn calories by raising metabolism and significantly enhances the benefits of regular exercise. The most recent clinical studies show significant increases in the benefits of exercise when consuming a single serving of Celsius before physical activity. Celsius contains Metaboost, a proprietary blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
